A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the SLXN SEC filings page.
Silexion Therapeutics Corp (SLXN) reported $134K in revenue over the twelve months to Sep 30, 2026. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Silexion remains a development-stage business: research spending dominates revenue, operating cash use is high, and FY2025 financing restored positive equity.
FY2025 operating cash flow was-$10.8M versus free cash flow of-$10.8M , so nearly all reported cash use came from operations rather than capital investment. R&D equaled4606.5% of revenue, identifying a development-stage cost structure in which research spending—not commercial scale—determines the earnings profile.
Funding, not operations, drove the FY2025 balance-sheet repair: financing cash flow was
The cost base is heavily research-led: R&D rose
Financial Health Signals
We do not publish a peer-relative financial health score for Silexion Therapeutics Corp, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Silexion Therapeutics Corp scores -15.24, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $55.2M against total assets of $7.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Silexion Therapeutics Corp passes 4 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 3 profitability signals pass, all 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) passes.
Silexion Therapeutics Corp reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Silexion Therapeutics Corp reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Silexion Therapeutics Corp generated $18K in revenue in Q3 2026. This represents a decrease of 53.8% from the same quarter a year earlier. Against the prior quarter it is up 28.6%.
Silexion Therapeutics Corp's EBITDA was -$2.7M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Silexion Therapeutics Corp reported a net loss of $2.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Silexion Therapeutics Corp recorded an outflow of $2.2M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Silexion Therapeutics Corp held $4.8M in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
Silexion Therapeutics Corp's quarterly ROE was -85.3% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 38.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7985.1 percentage points.
Not reported for Q3 2026.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Silexion Therapeutics Corp invested $1.3M in research and development in Q3 2026. This represents a decrease of 40.4% from the same quarter a year earlier. Against the prior quarter it is down 41.9%.
Silexion Therapeutics Corp invested $42K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q3 2026.
SLXN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'26S-1/A | Q4'25S-1/A | Q3'2510-Q | Q2'2510-Q | Q1'25S-1/A | Q4'24S-1/A |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18K-53.8% | $14K-68.2% | $32K+1500.0% | $70K | $39Kn/m | $44K+633.3% | $2K-89.5% | N/A |
| R&D Expenses | $1.3M-40.4% | $2.2M+117.3% | $1.4M+132.2% | $3.4M+287.5% | $2.2M-32.9% | $1.0M+32.9% | $590K-38.6% | $871K |
| SG&A Expenses | $1.4M+23.2% | $1.5M+16.0% | $1.4M+30.1% | $1.0M+0.2% | $1.1M-76.4% | $1.3M+104.5% | $1.1M+266.8% | $1.0M |
| Operating Income | -$2.7Mn/m | -$3.7Mn/m | -$2.7Mn/m | -$4.4Mn/m | -$3.3Mn/m | -$2.3Mn/m | -$1.6Mn/m | -$1.9M |
| EBITDA | -$2.7Mn/m | -$3.7Mn/m | -$2.7Mn/m | -$4.4M | -$3.3Mn/m | -$2.3Mn/m | -$1.6Mn/m | N/A |
| Interest Expense | $0n/m | $0n/m | $0-100.0% | $2K | $0n/m | $0n/m | $11Kn/m | N/A |
| Income Tax | N/A | N/A | N/A | $0-100.0% | $0-100.0% | $3K+50.0% | N/A | $1K |
| Net Income | -$2.5Mn/m | -$3.6Mn/m | -$2.7Mn/m | -$4.4M | -$3.3Mn/m | -$2.5Mn/m | -$1.7Mn/m | N/A |
| EPS (Basic) | $13.70 | $5.17 | $8.46 | N/A | -$0.69 | -$43.19 | $38.39 | N/A |
| EPS (Diluted) | $13.70 | $5.17 | $8.46 | N/A | -$691.14 | -$43.19 | $38.39 | N/A |
| Diluted Shares (Avg) | 184,927 | 687,353 | 323,038 | N/A | 4,720 | 57,952 | 45,198 | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
SLXN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'26S-1/A | Q4'25S-1/A | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'24S-1/A |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $6.8M-41.2% | $4.2M-26.8% | $4.6M-44.6% | $7.2M+152.0% | $11.6M+276.2% | $5.8M+150.4% | $8.3M+131.7% | $2.9M-45.5% |
| Current Assets | $6.1M-44.7% | $3.7M-28.6% | $4.1M-47.4% | $6.6M+195.0% | $11.1M+262.8% | $5.2M+126.2% | $7.7M | $2.3M-54.8% |
| Cash & Equivalents | $4.8M-48.5% | $2.2M-35.7% | $2.4M-60.8% | $6.0M+404.7% | $9.2M+368.5% | $3.5M+104.2% | $6.2M+117.3% | $1.2M-74.2% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $3.9M-16.8% | $4.2M-26.0% | $4.3M-24.7% | $4.6M-32.7% | $4.6M-39.5% | $5.7M-72.4% | $5.7M | $6.9M-66.9% |
| Current Liabilities | $3.7M+32.1% | $4.0M+84.9% | $4.1M+69.5% | $2.8M-21.7% | $2.8M-22.2% | $2.1M-9.1% | $2.4M | $3.5M+60.4% |
| Non-Current Liabilities | $178K-90.4% | $226K-93.6% | $251K-92.5% | $1.9M-44.3% | $1.9M-54.7% | $3.5M+43987.5% | $3.3M | $3.3M+5542.4% |
| Total Equity | $3.0M-57.5% | $44K-63.3% | $291K-88.7% | $2.6Mn/m | $7.0Mn/m | $120Kn/m | $2.6M | -$4.0Mn/m |
| Retained Earnings | -$64.0Mn/m | -$61.5Mn/m | -$57.9Mn/m | -$55.2Mn/m | -$50.8Mn/m | -$47.5Mn/m | -$45.0M | -$43.3Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
SLXN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'26S-1/A | Q4'25S-1/A | Q3'2510-Q | Q2'2510-Q | Q1'25S-1/A | Q4'24S-1/A |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.1Mn/m | -$2.9Mn/m | -$3.6Mn/m | -$3.0Mn/m | -$2.8Mn/m | -$2.5Mn/m | -$2.5Mn/m | -$2.9Mn/m |
| Depreciation & Amortization | $2K-50.0% | $3K0.0% | $2K-50.0% | $3K | $4K-81.8% | $3K-57.1% | $4K-50.0% | N/A |
| Stock-Based Compensation | $16K-57.9% | $197K+432.4% | $345K+1542.9% | N/A | $38K-99.3% | $37K+15.6% | $21K-34.4% | N/A |
| Capital Expenditures | $42Kn/m | $0-100.0% | $0-100.0% | $2Kn/m | $0-100.0% | $1Kn/m | $6K0.0% | $0-100.0% |
| Free Cash Flow | -$2.2Mn/m | -$2.9Mn/m | -$3.6Mn/m | -$3.0Mn/m | -$2.8Mn/m | -$2.5Mn/m | -$2.5Mn/m | -$2.9Mn/m |
| Investing Cash Flow | -$42Kn/m | -$1Kn/m | $0n/m | -$7Kn/m | $0n/m | -$1Kn/m | -$6Kn/m | $0n/m |
| Financing Cash Flow | $4.7M-45.5% | $2.7Mn/m | $83K-98.9% | -$221K-110.1% | $8.6M+195.3% | -$195Kn/m | $7.4M | $2.2Mn/m |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SLXN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'26S-1/A | Q4'25S-1/A | Q3'2510-Q | Q2'2510-Q | Q1'25S-1/A | Q4'24S-1/A |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -14911.1% | -26285.7% | -8590.6% | -6294.3% | -8441.0% | -5190.9% | -82500.0% | N/A |
| Net Margin | -14072.2% | -25364.3% | -8540.6% | -6302.9% | -8364.1% | -5688.6% | -86750.0% | N/A |
| Return on Equity | -85.3%-38.6pp | -8070.5%-5984.6pp | -939.2%-872.1pp | -169.5% | -46.8% | -2085.8% | -67.1% | N/A |
| Return on Assets | -37.1%-9.0pp | -83.6%-40.5pp | -59.4%-38.5pp | -61.2% | -28.1%+356.1pp | -43.2%+21.1pp | -20.9%+18.8pp | N/A |
| Current Ratio | 1.66-2.3x | 0.94-1.5x | 1.00-2.2x | 2.41+1.8x | 3.97+3.1x | 2.44+1.5x | 3.22 | 0.64-1.6x |
| Liabilities-to-Equity | 1.30+0.6x | 95.50+48.2x | 14.81+12.6x | 1.77 | 0.66 | 47.31 | 2.21 | N/A |
| Asset Turnover | 0.000.0x | 0.000.0x | 0.010.0x | 0.01 | 0.000.0x | 0.010.0x | 0.000.0x | N/A |
| FCF Margin | -11961.1% | -20892.9% | -11393.8% | -4311.4% | -7289.7% | -5700.0% | -122950.0% | N/A |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Silexion Therapeutics Corp SLXN | FY2025 | $155K | -$11.9M | N/A | $935K | — |
| Aptevo Therapeutics Inc APVO | FY2025 | N/A | -$26.0M | N/A | $943K | — |
| Artelo Biosciences, Inc. ARTL | FY2025 | N/A | -$12.9M | N/A | $1.4M | — |
| Genprex, Inc. GNPX | FY2025 | N/A | -$16.2M | N/A | $2.3M | — |
| Kairos Pharma, Ltd. KAPA | FY2025 | N/A | -$5.4M | N/A | $2.1M | — |
| Bone Biologics Corp BBLG | FY2025 | N/A | -$3.1M | N/A | $986K | — |
Where Silexion Therapeutics Corp Ranks
Frequently Asked Questions
Silexion Therapeutics Corp (SLXN) reported $155K in total revenue for fiscal year 2025. This represents a 453.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Silexion Therapeutics Corp (SLXN) revenue grew by 453.6% year-over-year, from $28K to $155K in fiscal year 2025.
No, Silexion Therapeutics Corp (SLXN) reported a net loss of $13.2M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $11.9M.
Silexion Therapeutics Corp (SLXN) had EBITDA of -$11.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Silexion Therapeutics Corp (SLXN) has a return on equity of -457.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Silexion Therapeutics Corp (SLXN) recorded an outflow of $10.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Silexion Therapeutics Corp (SLXN) had $7.2M in total assets as of fiscal year 2025, including both current and long-term assets.
Silexion Therapeutics Corp (SLXN) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Silexion Therapeutics Corp (SLXN) invested $7.1M in research and development during fiscal year 2025.
Silexion Therapeutics Corp (SLXN) had a current ratio of 2.41 as of fiscal year 2025, which is generally considered healthy.
Silexion Therapeutics Corp (SLXN) had a liabilities-to-equity ratio of 1.77 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Silexion Therapeutics Corp (SLXN) had a return on assets of -165.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Silexion Therapeutics Corp (SLXN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $935K as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Silexion Therapeutics Corp (SLXN) trades at 7.0x sales, its market capitalization divided by $134K revenue, trailing 12 months to September 30, 2026. The market capitalization is $935K as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Silexion Therapeutics Corp (SLXN) held $6.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $10.8M over that year. Dividing the one by the other, the reported balance equals about 7 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Silexion Therapeutics Corp (SLXN) has an Altman Z-Score of -15.24, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
Silexion Therapeutics Corp (SLXN) has a Piotroski F-Score of 4 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Silexion Therapeutics Corp (SLXN) reported a net loss of $11.9M while operations used $10.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Silexion Therapeutics Corp (SLXN) reported an operating loss of $11.6M against $13K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.